Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Summary

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Conditions

• Stage III Breast Cancer
• Stage IV Breast Cancer
• Stage III Lung Cancer
• Stage IV Lung Cancer
• AML
• Multiple Myeloma in Relapse
• Carcinoma
• Carcinoma, Pancreatic
• Carcinoma of Lung
• Carcinoma, Non-Small-Cell Lung
• Carcinoma Breast
• Carcinoma Prostate
• Carcinoma, Hepatocellular
• Carcinoma, Renal Cell
• Carcinoma, Neuroendocrine
• Carcinoma, Small Cell Lung
• Carcinoma, Ovarian
• Carcinoma Bladder
• Carcinoma of Esophagus
• Carcinoma Cervix
• Carcinoma, Thymic
• Carcinoma, Ductal
• Carcinoma of the Head and Neck
• Carcinoma of the Lip
• Carcinoma of the Oral Cavity
• Carcinoma of Unknown Primary
• Carcinoma of the Skin
• Carcinoma of the Anus
• Carcinoma of the Larynx
• Carcinoma of the Penis
• Carcinoma of the Oropharynx
• Carcinoma of the Appendix
• Carcinoma of the Paranasal Sinus
• Carcinoma of the Vulva
• Malignant Pleural Effusion
• Malignant Ascites
• Mesothelioma
• Cholangiocarcinoma

Sponsors & Collaborators

• Travera Inc

  lead INDUSTRY

Principal Investigators

• Mark Stevens, Ph.D. · Travera Inc

• Robert Kimmerling, Ph.D. · Travera Inc

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-11-30

Primary Completion

2028-05-31

Completion

2030-05-31